Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 6:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Vehicle foam Clear all
Completed Phase 3 Interventional Results available

Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)

NCT05028582
View directory record Official record
Conditions
Scalp Psoriasis
Interventions
Roflumilast Foam 0.3%, Vehicle Foam
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
36
States / cities
Scottsdale, Arizona • Beverly Hills, California • Encinitas, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Sep 19, 2026, 6:27 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Therapeutic Equivalence and Safety in Treatment of Moderate Facial Rosacea

NCT03689010
View directory record Official record
Conditions
Rosacea
Interventions
Azelaic acid foam 15%, Finacea® (Azelaic acid Foam) 15%, Vehicle of the test product
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 19, 2026, 6:27 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies

NCT00688519
View directory record Official record
Conditions
Psoriasis
Interventions
U0267, Vehicle
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
13
States / cities
San Diego, California • Denver, Colorado • Miami, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 1, 2017 · Synced Sep 19, 2026, 6:27 AM EDT
Completed Phase 3 Interventional Results available

A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea

NCT04608500
View directory record Official record
Conditions
Facial Papulopustular Rosacea
Interventions
FMX103 minocycline foam 1.5%, Vehicle foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
771 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
46
States / cities
Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Sep 19, 2026, 6:27 AM EDT
Completed Phase 3 Interventional Results available

Endovenous Ablation With and Without Polidocanol Endovenous Microfoam Treatment for Patients With Great Saphenous Vein Incompetence and Visible Varicosities

NCT01197833
View directory record Official record
Conditions
Great Saphenous Vein Incompetence, Visible Varicosities
Interventions
endovenous ablation+polidocanol injectable microfoam 0.125%, Endovenous ablation+polidocanol injectable microfoam 1.0%, Endovenous ablation+polidocanol injectable foam 2.0%
Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
7
States / cities
Scottsdale, Arizona • Bradenton, Florida • Oak Brook, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2021 · Synced Sep 19, 2026, 6:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of Enstilar Foam in Combination With Apremilast (Otezla) in Patients With Moderate Plaque Psoriasis

NCT03441789
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Enstilar, Vehicle, Otezla
Drug
Lead sponsor
L.H. Kircik, M.D.
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
4
States / cities
Sacramento, California • Louisville, Kentucky • Rockville, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Sep 19, 2026, 6:27 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea

NCT01555463
View directory record Official record
Conditions
Papulopustular Rosacea
Interventions
Azelaic acid foam, 15% (BAY39-6251), Vehicle foam
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
961 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
49
States / cities
Birmingham, Alabama • Fremont, California • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Sep 19, 2026, 6:27 AM EDT
Completed Phase 3 Interventional Results available

LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris

NCT01866163
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
LEO 90100, Vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 19, 2026, 6:27 AM EDT
Not listed Phase 2 Interventional

An Evaluation of PDI-320 in Comparison to Its Monads in Adults With Rosacea

NCT01828177
View directory record Official record
Conditions
Rosacea
Interventions
PDI-320, PDI-320 Monad #1, PDI-320 Monad #2, Vehicle
Drug
Lead sponsor
PreCision Dermatology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
San Diego, California • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Sep 19, 2026, 6:27 AM EDT
Completed Phase 2 Interventional

A Study to Compare FCD105 Foam to Minocycline 3% Foam, Adapalene 0.3% Foam and Vehicle Foam.

NCT04104685
View directory record Official record
Conditions
Acne Vulgaris
Interventions
FCD105, 3% Minocycline Foam, 0.3% Adapalene Foam, Vehicle Foam
Combination Product · Drug · Other
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
12 Years and older
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
35
States / cities
Bryant, Arkansas • Rogers, Arkansas • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Sep 19, 2026, 6:27 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis

NCT02367911
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
122-0551 Foam, Vehicle Foam
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
9
States / cities
Birmingham, Alabama • San Diego, California • Ormond Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Sep 19, 2026, 6:27 AM EDT
Completed Phase 2 Interventional Results available

LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris

NCT01536886
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
LEO 90100, Betamethasone plus calcipotriol, Ointment vehicle, LEO 90100 vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
39
States / cities
Hot Springs, Arkansas • Los Angeles, California • Oceanside, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Sep 19, 2026, 6:27 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Enstilar Versus Vehicle on Target Lesions in Moderate Plaque Type Psoriasis Patients

NCT03848871
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Enstilar
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 25, 2020 · Synced Sep 19, 2026, 6:27 AM EDT
Completed Phase 2 Interventional Results available

A Dose Ranging Vehicle Controlled Study to Determine the Safety and Efficacy of Permethrin Foam, 5% and Permethrin Foam, 4% for the Treatment of Scabies

NCT02094716
View directory record Official record
Conditions
Scabies
Interventions
Permethrin Foam 4%, Permethrin Foam 5%, Vehicle Foam
Drug
Lead sponsor
Mylan Inc.
Industry
Eligibility
6 Months and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
5
States / cities
Fremont, California • Los Angeles, California • Hialeah, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Sep 19, 2026, 6:27 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis

NCT04091646
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
Roflumilast Foam 0.3%, Vehicle foam
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
22
States / cities
Fremont, California • Santa Monica, California • Coral Gables, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2023 · Synced Sep 19, 2026, 6:27 AM EDT
Completed Phase 3 Interventional Results available

Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)

NCT04973228
View directory record Official record
Conditions
Seborrheic Dermatitis
Interventions
Roflumilast Foam, Vehicle Foam
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
9 Years and older
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
43
States / cities
Scottsdale, Arizona • Encinitas, California • San Diego, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 19, 2026, 6:27 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis

NCT04128007
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Roflumilast foam 0.3%, Vehicle foam
Drug
Lead sponsor
Arcutis Biotherapeutics, Inc.
Industry
Eligibility
12 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
31
States / cities
Rogers, Arkansas • Fremont, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Sep 19, 2026, 6:27 AM EDT
Completed Phase 2 Interventional

Comparative PK Study of Econazole Nitrate Foam and Econazole Nitrate Cream in Subjects With Interdigital Tinea Pedis Aged 12 Years to Less Than 18 Years

NCT01696799
View directory record Official record
Conditions
Interdigital Tinea Pedis
Interventions
Econazole Nitrate, placebo
Drug
Lead sponsor
AmDerma
Industry
Eligibility
12 Years to 18 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 30, 2012 · Synced Sep 19, 2026, 6:27 AM EDT
Completed Phase 3 Interventional Results available

A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris

NCT02267746
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene (Fabior™), Tazarotene (Actavis), Vehicle foam
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
893 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
14
States / cities
Encino, California • Fremont, California • Brandon, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Sep 19, 2026, 6:27 AM EDT
Completed Phase 3 Interventional Results available

LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris

NCT02899962
View directory record Official record
Conditions
Psoriasis Vulgaris
Interventions
LEO 90100 aerosol foam, LEO 90100 aerosol foam vehicle
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
722 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
21
States / cities
Fremont, California • Santa Monica, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2020 · Synced Sep 19, 2026, 6:27 AM EDT
Completed Phase 4 Interventional Results available

Enstilar® Foam in the Treatment of Chronic Plaque Psoriasis in Patients With Skin of Color

NCT03506477
View directory record Official record
Conditions
Plaque Psoriasis, Psoriasis
Interventions
Enstilar® foam, Vehicle foam
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 19, 2021 · Synced Sep 19, 2026, 6:27 AM EDT
Completed Phase 2 Interventional

An Evaluation of PDI-192 0.1% in Comparison to PDI-192 0.15% in the Treatment of Mild to Moderate Atopic Dermatitis

NCT01826461
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PDI-192, Vehicle
Drug
Lead sponsor
PreCision Dermatology, Inc.
Industry
Eligibility
3 Months to 17 Years
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
9
States / cities
San Diego, California • Chicago, Illinois • Normal, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Sep 19, 2026, 6:27 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301

NCT01017146
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene foam, Vehicle Foam
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years to 45 Years
Enrollment
744 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
19
States / cities
Denver, Colorado • Miami Beach, Florida • Indianapolis, Indiana + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2017 · Synced Sep 19, 2026, 6:27 AM EDT
Completed Phase 3 Interventional Results available

A Comparison of 122-0551 Foam Versus Vehicle Foam in Subjects With Plaque Psoriasis (Study 306)

NCT02368210
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
122-0551 Foam, Vehicle Foam
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
8
States / cities
Fremont, California • Miami, Florida • Arlington Heights, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2018 · Synced Sep 19, 2026, 6:27 AM EDT